New clotting factor could mean fewer shots for hemophilia a
NCT ID NCT05042440
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early study tested a new clotting factor called efanesoctocog alfa (BIVV001) in 13 adults with severe hemophilia A. The goal was to see how long it stays in the body compared to standard and extended half-life factors. Participants received single injections of each type in a fixed order. The study is complete and focused on safety and drug levels, not on preventing bleeds.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Efanesoctocog alfa (BIVV001), a longer-lasting clotting factor
- What this could lead to
- If it works, this could mean fewer injections for people with hemophilia A, making treatment easier.
- What could go wrong
- This is a very early, small study (13 people) only looking at how the drug moves in the body, not whether it prevents bleeding. It may not work better than existing treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMOPHILIA A are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Investigational Site Number :1000001
Sofia, 1756, Bulgaria
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A Once-a-Week shot could transform hemophilia Care—Even for those with inhibitors
- Can a new clotting factor offer better bleed protection for severe hemophilia?
- Do newer hemophilia drugs protect joints better? study aims to find out
- New clotting factor aims to cut bleeding episodes in severe hemophilia a
- Newborn screening study aims to catch rare diseases at birth
- New clotting factor aims to stop bleeding in severe hemophilia a